secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTEGRATED BIOPHARMA INC (INBP)
CIK:        0001016504
Form:       8-K
Filed at:   2023-03-17T23:59:59+00:00
Accession:  0001437749-23-007022
Event type: debt
Sentiment:  neutral
Materiality: 0.15
LLM model:  deepseek-v4-flash:cloud@v2

Integrated BioPharma amends credit agreement to replace LIBOR with Term SOFR plus 0.10%
--------------------------------------------------------------------------------

- Fourth Amendment to Revolving Credit, Term Loan and Security Agreement dated March 16, 2023.
- Interest rate benchmark changed from LIBOR to Term SOFR Rate plus a 10 basis point SOFR Adjustment.
- Outstanding LIBOR-based loans may remain until their term; new requests use Term SOFR.
- As of March 16, 2023, no outstanding borrowings or pending requests under the agreement.
- Amendment involves Integrated BioPharma and its subsidiaries with PNC Bank as agent.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1016504/000143774923007022/0001437749-23-007022-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1016504/000143774923007022/inbp20230316_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-007022

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer